Juvenile Idiopathic Arthritis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of juvenile idiopathic arthritis (JIA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of JIA for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s JIA forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of JIA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 11 JIA patient populations, as follows:
- Diagnosed incident cases of JIA.
- Diagnosed prevalent cases of JIA.
- Diagnosed prevalent cases of rheumatoid factor-positive (RF+) polyarthritis.
- Diagnosed prevalent cases of RF-negative (RF-) polyarthritis.
- Diagnosed prevalent cases of persistent oligoarthritis.
- Diagnosed prevalent cases of extended oligoarthritis.
- Diagnosed prevalent cases of enthesitis-related arthritis.
- Diagnosed prevalent cases of psoriatic arthritis.
- Diagnosed prevalent cases of undifferentiated arthritis.
- Diagnosed prevalent cases of systemic arthritis.
- Diagnosed prevalent cases of JIA-related uveitis.
Note: Coverage may vary by country.
